Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $272.54 in the prior trading day, West Pharmaceutical Services, Inc (NYSE: WST) closed at $267.56, down -1.83%. In other words, the price has decreased by -$1.83 from its previous closing price. On the day, 0.83 million shares were traded. WST stock price reached its highest trading level at $272.395 during the session, while it also had its lowest trading level at $265.385.
Ratios:
Our goal is to gain a better understanding of WST by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 30.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 50.78. For the most recent quarter (mrq), Quick Ratio is recorded 2.18 and its Current Ratio is at 2.87. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Morgan Stanley on December 02, 2025, initiated with a Equal-Weight rating and assigned the stock a target price of $285.
On September 15, 2025, Rothschild & Co Redburn started tracking the stock assigning a Buy rating and target price of $311.
On June 24, 2025, Barclays started tracking the stock assigning a Equal Weight rating and target price of $245.Barclays initiated its Equal Weight rating on June 24, 2025, with a $245 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WST now has a Market Capitalization of 19249178624 and an Enterprise Value of 18923679744. As of this moment, West’s Price-to-Earnings (P/E) ratio for their current fiscal year is 39.63, and their Forward P/E ratio for the next fiscal year is 34.33. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.66. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.38 while its Price-to-Book (P/B) ratio in mrq is 6.30. Its current Enterprise Value per Revenue stands at 6.27 whereas that against EBITDA is 23.613.
Stock Price History:
The Beta on a monthly basis for WST is 1.17, which has changed by -0.17554528 over the last 52 weeks, in comparison to a change of 0.13613915 over the same period for the S&P500. Over the past 52 weeks, WST has reached a high of $348.90, while it has fallen to a 52-week low of $187.43. The 50-Day Moving Average of the stock is -2.22%, while the 200-Day Moving Average is calculated to be 11.35%.
Shares Statistics:
The stock has traded on average 691.41K shares per day over the past 3-months and 622220 shares per day over the last 10 days, according to various share statistics. A total of 71.90M shares are outstanding, with a floating share count of 71.50M. Insiders hold about 0.62% of the company’s shares, while institutions hold 97.88% stake in the company. Shares short for WST as of 1764288000 were 2064220 with a Short Ratio of 2.99, compared to 1761868800 on 1433848. Therefore, it implies a Short% of Shares Outstanding of 2064220 and a Short% of Float of 3.7699999999999996.
Dividends & Splits
In the trailing 12 months, WST’s forward annual dividend rate was 0.84, compared to 0.85 this year. Against a Trailing Annual Dividend Yield of 0.0030821161. The stock’s 5-year Average Dividend Yield is 0.24. The current Payout Ratio is 12.27% for WST, which recently paid a dividend on 2025-11-12 with an ex-dividend date of 2026-01-28. Stock splits for the company last occurred on 2013-09-27 when the company split stock in a 2:1 ratio.
Earnings Estimates
The market rating of West Pharmaceutical Services, Inc (WST) is currently shaped by the ongoing analysis conducted by 13.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.65, with high estimates of $1.72 and low estimates of $1.56.
Analysts are recommending an EPS of between $7.24 and $7.02 for the fiscal current year, implying an average EPS of $7.1. EPS for the following year is $7.78, with 16.0 analysts recommending between $8.38 and $7.39.
Revenue Estimates
11 analysts predict $795.31M in revenue for. The current quarter. It ranges from a high estimate of $800M to a low estimate of $790.39M. As of. The current estimate, West Pharmaceutical Services, Inc’s year-ago sales were $748.8MFor the next quarter, 11 analysts are estimating revenue of $759.98M. There is a high estimate of $779.72M for the next quarter, whereas the lowest estimate is $742.81M.
A total of 15 analysts have provided revenue estimates for WST’s current fiscal year. The highest revenue estimate was $3.07B, while the lowest revenue estimate was $3.06B, resulting in an average revenue estimate of $3.06B. In the same quarter a year ago, actual revenue was $2.89BBased on 15 analysts’ estimates, the company’s revenue will be $3.26B in the next fiscal year. The high estimate is $3.34B and the low estimate is $3.22B.
